ABBV vs MAR: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Marriott International, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-18.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
Marriott International, Inc. · Consumer Cyclical
$377.93
-16.6% upside to fair value
Grade D
QuantHub Verdict
ABBV has more upside to fair value
(+4.5%).
ABBV trades at a lower forward P/E
(14.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
MAR |
| Current Price |
$208.05 |
$377.93 |
| Fair Value Estimate |
$217.50 |
$315.15 |
| Upside to Fair Value |
+4.5%
|
-16.6%
|
| Market Cap |
$367.9B |
$100.2B |
| Forward P/E |
14.9x
|
39.0x
|
| EV / EBITDA |
16.7x
|
25.3x
|
| Price / Sales |
6.1x
|
3.8x
|
| Price / FCF |
20.9x
|
34.6x
|
| Revenue Growth YoY |
+8.6%
|
+3.1%
|
| Gross Margin |
83.7%
|
21.3%
|
| Operating Margin |
34.7%
|
15.8%
|
| Return on Equity |
-129.24%
|
-79.9%
|
| Dividend Yield |
3.2% |
0% |
| FCF Yield |
4.78%
|
2.89%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
Marriott International operates the world's largest hospitality portfolio with approximately 8,900 to 9,000 properties across 141 countries and over 30 brands, supported by the largest loyalty program with 203 to 210 million members. The company benefits from a durable competitive moat driven by scale, brand strength, and network effects. However, despite steady revenue growth of 3.1% year-over-y…
Accumulation Zones
| Metric |
ABBV |
MAR |
| Zone Low |
$163.13 |
$236.36 |
| Zone High |
$184.88 |
$267.88 |
| In Buy Zone? |
No
|
No
|